(2024)
Beneficial microbiome and diet interplay in early-onset colorectal cancer.
EMBO Mol Med
[Accepted]
![Gianni Panagiotou](assets/images/a/panagiotou-gianni-9b44c810.jpg)
Prof. Dr. Gianni Panagiotou
Microbiome Dynamics · Leitung +49 3641 532-1759 gianni.panagiotou@leibniz-hki.deCurriculum vitae
Forschungsschwerpunkte
- Medizinische & Umweltmetagenomik: Mensch, Maus, Pflanzen, marine Lebewesen
- Systembiologie: Integration von –omics-Daten; Molekül/ Protein & Protein/ Protein Netzwerke
- Synthetische Biologie: Metabolische Modellierung auf Genomausmaß, Design von Probiotika, Entdeckung von Postbiotika
Publikationen
(2023)
High-throughput profiling of Candida auris isolates reveals clade-specific metabolic differences.
Microbiol Spectr 11(3),
e0049823.
(Review)
(2023)
Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation.
Nat Immunol 24(2),
295-308.
(2023)
Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions.
Microbiome 11(1),
178.
(2023)
Gut ecological networks reveal associations between bacteria, exercise and clinical profile in non-alcoholic fatty liver disease patients.
mSystems 8(5),
e0022423.
(2023)
Pathogen-specific innate immune response patterns are distinctly affected by genetic diversity.
Nat Commun 14(1),
3239.
(2023)
Disruption of the A. fumigatus RNA interference machinery alters the conidial transcriptome.
RNA 29(7),
1033-1050.
(2023)
Impaired flux of bile acids from the liver to the gut reveals microbiome-immune interactions associated with liver damage.
NPJ Biofilms and microbiomes 9(1),
35.
(2023)
Genome-scale Metabolic modeling of Aspergillus fumigatus strains reveals growth dependencies on the lung microbiome.
Nat Commun 14(1),
4369.
(2023)
Resistant starch decreases intrahepatic triglycerides in NAFLD patients via gut microbiome alterations.
Cell Metab 35(9),
1530-1547.